c-MYC is a radiosensitive locus in human breast cells

Ionising radiation is a potent human carcinogen. Epidemiological studies have shown that adolescent and young women are at increased risk of developing breast cancer following exposure to ionising radiation compared with older women, and that risk is dose-dependent. Although it is well understood which individuals are at risk of radiation-induced breast carcinogenesis, the molecular genetic mechanisms that underlie cell transformation are less clear. To identify genetic alterations potentially responsible for driving radiogenic breast transformation, we exposed the human breast epithelial cell line MCF-10A to fractionated doses of X-rays and examined the copy number and cytogenetic alterations. We identified numerous alterations of c-MYC that included high-level focal amplification associated with increased protein expression. c-MYC amplification was also observed in primary human mammary epithelial cells following exposure to radiation. We also demonstrate that the frequency and magnitude of c-MYC amplification and c-MYC protein expression is significantly higher in breast cancer with antecedent radiation exposure compared with breast cancer without a radiation aetiology. Our data also demonstrate extensive intratumor heterogeneity with respect to c-MYC copy number in radiogenic breast cancer, suggesting continuous evolution at this locus during disease development and progression. Taken together, these data identify c-MYC as a radiosensitive locus, implicating this oncogenic transcription factor in the aetiology of radiogenic breast cancer.


INTRODUCTION
Ionising radiation is a potent human carcinogen. Several tissues and organs are susceptible to the transforming effects of ionising radiation, including the breast in adolescent and young women in whom risk is both dose-and age-dependent. 1 In women treated with radiotherapy for Hodgkin lymphoma, there is a linear relationship between radiation exposure and breast cancer risk, with those under the age of 20 years at the time of exposure at the highest risk of developing subsequent breast cancer. 2 Similarly, young women exposed to radiation after the atomic bombs of Hiroshima and Nagasaki 3-5 and those exposed to high levels of diagnostic radiation [6][7][8][9] have an elevated risk of breast cancer.
The molecular genetic mechanisms that lead to radiogenic breast cancer are unclear, but there is evidence that cancers subsequent to radiation exposure have genotypic and phenotypic features that distinguish them from other breast cancers, and are more likely to be of the HER2 or basal-like subtypes. 10 Furthermore, array comparative genomic hybridisation and expression microarray analyses demonstrate that radiogenic breast cancers cluster separately from other breast cancers 10,11 and have a higher degree of genetic instability, such as a higher frequency of allelic loss of chromosome bands 6q13-q14 and 9p21. 12,13 Specific alterations have been implicated in radiogenic breast transformation, [14][15][16][17][18] but there is no evidence that any of these genetic changes are induced directly by radiation exposure.
Understanding the pathogenesis and underlying molecular genetic alterations that drive radiogenic breast cancer could facilitate early detection in those who have been exposed to high levels of ionising radiation and help tailor subsequent therapy. To this end, we have used human cell model systems to identify cytogenetic and copy number alterations induced by in vitro exposure to ionising radiation, and determined the frequency of these alterations in breast cancer patients with and without antecedent radiation exposure.

Acquired copy number alterations in irradiated MCF-10A breast epithelial cells
MCF-10A cells were irradiated with fractionated doses of X-rays to a cumulative dose of 80 Gy using four independent dosing regimens (two using 5 Gy and two using 10 Gy fractions), and copy number alterations in irradiated cells were assessed by high-density singlenucleotide polymorphism (SNP) array analysis (Affymetrix SNP6.0, Affymetrix, La Jolla, CA, USA) by comparison with parental MCF-10A. A number of large-scale and focal copy number alterations were identified (Supplementary Tables 1-3), including a 2.5 Mb focal copy number gain affecting the c-MYC proto-oncogene on 8q in one of the 5 Gy dosing regimens (Supplementary Table 1). Given the established role of c-MYC in breast cancer pathogenesis, the aetiology and evolution of this alteration was investigated in cells that had received a cumulative radiation dose of 20, 40, 60 and 80 Gy. Comparison with parental MCF-10A indicated no discernible copy number alterations in cells that had received a cumulative dose of 20 Gy. However, in the 40 Gy cumulative dose population, the 2.5 Mb copy number gain of 8q, which includes the c-MYC, PVT1 and TMEM75 genes, first became discernible (Figure 1a and Supplementary Table 1). This gain occurred within a 46 Mb region of chromosome 8q with an inherent copy number of 3 in parental MCF-10A. 19 In the 60Gy cumulative dose population, a further copy number gain of ~ 59 Mb was apparent for chromosome 8q, which included and extended beyond the 46 Mb region of copy number gain present in parental MCF-10A (Figure 1a and Supplementary Table 1). The telomeric breakpoint of the ~ 59 Mb gain was unclear, but appeared to be located within the focal 2.5 Mb copy number gain encompassing c-MYC. The array profile of the 80 Gy cumulative dose population was broadly similar to that observed in the 60Gy population, although the large ~ 59 Mb copy number gain and the focal 2.5 Mb copy number gain encompassing c-MYC were more prominent features.
To further define the breakpoints in the proximity of the c-MYC locus, we isolated 15 independent cell clones from the 80 Gy population via limiting dilution and analysed these using very high-density SNP arrays (Affymetrix Cytoscan). These data identified two major sub-populations with distinct breakpoints in the proximity of the c-MYC locus ( Figure 1b). All 15 clones carried the 2.5 Mb focal copy number gain affecting the c-MYC locus first identified in the 40 Gy population. Twelve of the 15 clones carried the additional ~ 59 Mb copy number gain discernible from SNP6.0 data. Furthermore, these additional high-density SNP data demonstrated that the telomeric breakpoint was located within PVT1 (Supplementary Figure 1). This major clone also carried a deletion affecting the p-arm of chromosome 8 (telomere-13 726 906). Three of the 15 clones did not carry the ~ 59 Mb copy number gain or the p-arm deletion described above. Rather, these clones carried a novel copy number gain also encompassing c-MYC (75 234 254-telomere), which was not discernible from the SNP6.0 data, presumably because these cells constituted a minor subpopulation. Taken together, these data suggest that these two sub-populations, with additional alterations affecting the c-MYC gene, share an ancestral clone carrying the focal 2.5 Mb amplification. This model demonstrates additional breaks in the proximity of c-MYC and ongoing evolution of this locus as a result of cumulative radiation exposure.

c-MYC alterations in parental and irradiated MCF-10A breast epithelial cells
The allelic location, magnitude and orientation of the alterations affecting c-MYC in parental MCF-10A and cells from the 80 Gy irradiated population were assessed by cytogenetic and meta-phase fluorescence in situ hybridisation (FISH) analysis. The region of 8q gain present in parental MCF-10A cells was shown to be a duplication and subsequent inversion to the end of chromosome 8p, which results in a derivative chromosome, der(8)t(8;8)(q22; p23) ( Figure 2a).
The large ~ 59 Mb gain first identified in the 60 Gy population and generated via the break in PVT1 is a tandem duplication of the 8q12-q24 region of the normal chromosome 8 giving rise to dup (8)(q12-q24) (Figure 2b). FISH identified multiple copies of c-MYC at both the expected 8q24 bands on the dup(8)(q12-q24) chromosome (Figure 2b, inset), demonstrating that the ~ 59 Mb duplication and the focal amplification are on the same allele. No evidence that the ~ 59 Mb duplication preceded the focal amplification was provided by metaphase FISH, and supports the SNP array data in suggesting that the PVT1 break and ~ 59 Mb duplication occurred subsequent and independent to the 2.5 Mb focal amplification.
Additional alterations that affected the c-MYC locus were identified in minor subpopulations of cells that had received a cumulative dose of 80 Gy (Supplementary Figure 2) and included a translocation to an unidentified partner chromosome, a further duplication of the der(8)t(8;8)(q22;p23) and a second tandem duplication on the dup(8)(q12-q24).

Copy number gain of c-MYC results in increased c-MYC protein expression
Concomitant with c-MYC amplification, c-MYC protein expression was higher in cells irradiated with a cumulative dose of 40 Gy or greater compared with parental cells (one-way analysis of variance, P<0.001) (Figures 3c and d). These data demonstrate that low doses of ionising radiation induce copy number alterations in human MCF-10A cells, and that c-MYC is susceptible to multiple structurally diverse alterations, including high-level amplification, which results in increased expression of c-MYC protein.

c-MYC alterations in primary HuMECs
To exclude the possibility that radiation-induced c-MYC copy number gain was specific to immortalised cells, we next treated low passage human mammary epithelial cells (HuMECs) with ionising radiation and determined c-MYC copy number using FISH. Cells were treated with an initial dose of 2 Gy and subsequently treated with an additional dose of either 1 or 2 Gy, giving total cumulative doses of 2, 3 and 4 Gy. Using FISH probes for c-MYC, centromere 8 and IGH, we found evidence of polyploidy in all cell populations, including mock-treated control HuMECs. Interphase FISH provided no evidence for specific c-MYC amplification in mock-treated HuMECs ( Figure

c-MYC alterations in radiogenic breast cancer after Hodgkin lymphoma
We investigated c-MYC copy number alterations and protein expression in breast cancer following radiotherapy for Hodgkin lymphoma ('radiogenic breast cancer (RAD)', n = 18; Supplementary Table 4) and age-matched cases for which there was no evidence of radiation exposure aetiology ('sporadic breast cancer (SPO)', n = 33; Supplementary Table 5).
c-MYC copy number was assessed by FISH and was successful for 20 of 33 (61%) sporadic breast cancer samples and 9 of 18 (50%) radiogenic breast cancer samples. c-MYC copy number was higher in radiogenic compared with sporadic breast cancer (Mann-Whitney Utest, P = 0.027; Figure 4a; Supplementary Tables 6 and 7). Furthermore, 4 of 9 (44%) radiogenic breast cancer cases had at least 10% of nuclei with 6 or more c-MYC signals, compared with only 1 of 20 (5%) sporadic breast cancer cases (Fisher's exact test, P = 0.022; Figure 4b).

Mechanisms and magnitude of c-MYC copy number gains in radiogenic breast cancer
The pattern of centromere 8 and c-MYC hybridisation was studied in each sample to investigate the mechanisms that underlie the increase in c-MYC copy number. Although the majority of nuclei in all the samples were diploid for chromosome 8, most samples also had nuclei with more than two copies of centromere 8 (Supplementary Table 6). In some cases (e.g. SPO11 and SPO17), there were nuclei with over six centromere 8 signals. Likewise, the majority of samples had nuclei with apparent monosomy 8. These data demonstrate a high level of both intra-and intertumour heterogeneity with respect to chromosome 8 copy number status. We determined the ratio between mean c-MYC and chromosome 8 signals to identify cases with specific c-MYC locus amplification. There was a higher c-MYC to centromere 8 ratio in radiogenic breast cancer compared with sporadic breast cancer (Mann-Whitney U-test, P = 0.016) ( Figure 4c). Furthermore, more radiogenic breast cancers (7 of 9, 77%) than sporadic breast cancers (4 of 20, 20%) had a c-MYC to centromere 8 ratio >1.10 (Fisher's exact test, P = 0.010; Figure 4d), indicating that locus-specific c-MYC copy number gain is more common in radiogenic breast cancer.
Two sporadic (e.g. SPO2, SPO28) and two radiogenic cases (e.g. RAD9, RAD10) had high c-MYC to centromere 8 ratios (>1.25) with evidence of high-level c-MYC locus amplification in the majority of nuclei (Supplementary Tables 6 and 7). Dual hybridisation analysis of these four c-MYC-amplified cases demonstrated that the magnitude of c-MYC copy number gain was higher in the radiogenic breast cancers compared with the sporadic cancers ( Figure 5). Specifically, for SPO2 and SPO28, the majority of nuclei with c-MYC amplification had five and three c-MYC signals, respectively, and included cells with up to seven and four c-MYC signals, respectively (Figure 5b and Supplementary Table 6). For RAD9 and RAD10, the majority of nuclei with c-MYC amplification had 5 and 9 c-MYC FISH signals, respectively, and included cells with up to 13 and 14 c-MYC signals, respectively (Figure 5b and Supplementary Table 6).
Taken together, these data indicate that c-MYC copy number gain is more common in radiogenic breast cancer than in sporadic disease, and that a greater proportion of radiogenic samples have c-MYC copy number gains that affect specifically the c-MYC locus.

c-MYC expression in radiogenic breast cancer and correlation with c-MYC copy number
We determined c-MYC protein expression in radiogenic and sporadic breast cancers by immunohistochemistry and derivation of a histoscore (Supplementary Figure 4). There was a trend towards higher expression of c-MYC in the radiogenic breast cancer compared with sporadic breast cancer (Figure 6a; Mann-Whitney U-test, P = 0.119). Tumours in which c-MYC immunoreactivity was detected in <10% of cells were considered to be negative for expression (8 radiogenic (44%) and 16 sporadic breast cancer cases (48%)). An analysis of all cases suggested that exposure to ionising radiation was not associated with c-MYCpositivity (χ 2 = 0.076: P = 0.782). However, comparison of protein expression in c-MYCpositive tumours demonstrated that the expression was significantly higher in the radiogenic breast cancer compared with sporadic breast cancer (Figure 6b; Mann-Whitney U-test: P<0.001).
Samples were divided into three groups on the basis of c-MYC protein expression: no or low c-MYC expression (histoscore: 0-50), moderate expression (histoscore: 51-100) and high expression (histoscore: >100). The proportion of samples with no or low, moderate or high c-MYC expression were different between the radiogenic and sporadic cases, with high c-MYC expression significantly more common in the radiogenic series ( Figure 6c; χ 2 = 8.041; P = 0.018).
We investigated if there was a correlation between c-MYC gene copy number and protein expression and if there was a trend towards higher c-MYC expression in samples with a mean c-MYC copy number ≥ 3 (n = 7) compared with samples with a c-MYC copy number <3 (n = 22) (Mann-Whitney U-test, P = 0.115; Figure 6d), although there was inconsistency between c-MYC copy number and c-MYC protein expression in several cases (Supplementary Table 8). In summary, these data demonstrate that c-MYC expression is higher in radiogenic breast cancer compared with sporadic disease. In some tumours, high c-MYC copy number is reflected in high c-MYC protein expression but in others the additional copies of c-MYC do not result in high levels of protein expression.

DISCUSSION
We identified ionising radiation-induced genetic alterations affecting c-MYC in immortalised non-transformed breast epithelial cells that include high-level focal amplification, duplication and translocation. A particular strength of our study is that c-MYC amplification was generated directly by ionising radiation in a controlled experimental system. Previous studies have suggested that c-MYC amplification is a late-stage event in radiation-induced transformation. 20,21 However, detailed single-cell analysis in this study has identified several structurally diverse alterations of c-MYC after relatively low radiation doses of 10-20 Gy. We also identified high-level c-MYC amplification in primary mammary epithelial cells following radiation doses between 2 and 4 Gy.
High-level c-MYC amplification was more common in human breast cancer, which developed after radiotherapy compared with breast cancer without antecedent radiation exposure, providing additional evidence that ionising radiation specifically induces c-MYC amplification and implicates radiotherapy as one cause of 8q alterations in radiogenic breast cancer. In support of this supposition, recurrent amplification of the c-MYC locus has been reported in breast cancers that developed in atomic bomb survivors. 14 Detailed single-cell analysis also revealed considerable intra-and intertumour heterogeneity with respect to c-MYC copy number in human radiogenic breast cancer, suggesting continuous evolution at this locus during disease development and progression. Taken together, these observations suggest progressive accumulation of alterations and provide strong evidence that this locus is particularly sensitive to radiation-induced alteration.
There is evidence suggesting that c-MYC is intrinsically unstable in human breast cells. Kadota et al. 22 identified a spontaneous single-copy c-MYC gain in MCF-10A cells, but there was no evidence of high-level amplification. The breakpoints of the single-copy gain do not match those reported in our study, which are associated with high-level focal c-MYC amplification. Diverse breakpoints suggest several putative fragile sites at the c-MYC locus. Common fragile sites with a particular propensity to undergo breakage during replication stress exist in the human genome. 23 Two such common fragile sites, FRA8C and FRA8D, flank c-MYC and breakage at these sites have been identified in cervical cancer and Burkitt lymphoma. 24 Furthermore, radiation-induced genotoxic stress, which in turn induces replication stress, has been shown to induce breaks at fragile sites in the rat genome. 25 Our study has clearly demonstrated an association between antecedent radiation exposure and elevated expression of c-MYC in breast cancer. A clear link between radiation-induced c-MYC amplification and elevated c-MYC protein expression was demonstrated in vitro using cultured human breast cells. This association was also seen in breast cancer tissue, although the correlation was relatively weak. Reports of a weak correlation between c-MYC copy number and protein expression in cancer are common, and have been described in breast, pancreatic, bladder and colon disease. [26][27][28][29] Expression of c-MYC is regulated by multiple pathways and is known to be highly regulated by cell cycle state (quiescence/ proliferation), irrespective of whether there is gene amplification. 30

Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts which c-MYC protein expression does not increase with gene copy number could indicate a low proliferative index or mechanisms disrupting transcription/protein stability.
Furthermore, a mechanism has been identified that could be responsible for increased c-MYC expression in radiogenic breast cancer without the requirement of c-MYC amplification. Best et al. 32 identified a risk haplotype for radiogenic breast cancer at the PRDM1 (BLIMP1) locus on 6q. PRDM1 is a negative transcriptional regulator of c-MYC and the risk haplotype is associated with reduced PRDM1 expression, attenuated upregulation of PRDM1 and increased expression of c-MYC in response to ionising radiation. The findings of our study and the identification of the PRDM1 risk haplotype strongly suggest an important role for c-MYC overexpression in radiogenic breast cancer development, and we can speculate that radiation-induced c-MYC amplification may be an important driver of c-MYC dysregulation in some, but not all, cases of radiogenic breast cancer.
c-MYC is a well-established proto-oncogene, which when overexpressed drives cell proliferation, 30,33,34 blocks cell differentiation, 34,35 promotes angiogenesis 36 and genetic instability. 37,38 Overexpression of c-MYC has been associated with radiation resistance, which could confer a survival advantage during a fractioned therapeutic dosing regimen and could be an important phenotype required for cell transformation. [39][40][41][42] The application of targeted therapy against cells with dysregulated c-MYC expression 43 could therefore prove efficacious in the treatment of radiogenic breast cancer and might have value to prophylactically inhibit the outgrowth of c-MYC deregulated cells following radiation exposure.
In conclusion, this study demonstrates that ionising radiation directly induces genetic alterations affecting c-MYC, including translocation and high-level focal amplification, and identifies c-MYC as a radiosensitive locus. Importantly, c-MYC protein expression was significantly elevated in radiation-exposed breast cells, emphasising the importance of this critical transcription factor in radiogenic breast cancer. Our findings provide insight into the aetiology of radiogenic breast cancer and may have relevance to other cancers with a radiation exposure aetiology.

Primary mammary epithelial cells (HuMECs) and MCF-10A cells
HuMECs were obtained from Gibco (Life Technologies, Paisley, UK) and maintained in HuMEC Ready Medium (Life Technologies). MCF-10A cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in the medium as described previously 44 supplemented with 10 nM 17-β oestradiol. MCF-10A cells are a non-transformed breast epithelial cell line derived from non-malignant human fibroblastic mammary tissue immortalised by extended cultivation in low calcium concentrations. 45 The karyotype of MCF-10A is near diploid with a t(3;9)(p13;p22) and an unbalanced translocation between part of chromosome 5 to the short arm of the derivative chromosome 9, which results in a deletion of CDKN2A/CDKN2B, which is thought be responsible for the immortalisation of this cell line. MCF-10A carries a duplication of part

Europe PMC Funders Author Manuscripts
Europe PMC Funders Author Manuscripts of the long arm of chromosome 8 (8q), trisomy for chromosome 20, trisomy for the long arm of chromosome 1 (1q) and an additional copy of chr1: 198 136 766-qter (19).

Irradiation of MCF-10A and HuMECs
MCF-10A cells were exposed to 5 and 10 Gy fractionated doses of X-irradiation (2.5 Gy/ min) to a cumulative dose of 80 Gy using a D3300 X-ray system (Gulmay Medical Ltd, Chertsey, UK). To test the stability of MCF-10A cells in continuous culture, unirradiated cells were cultured under the same conditions and for the same length of time as irradiated cells (termed 'untreated MCF-10A'). Clonal populations of cells that had received a cumulative dose of 80 Gy were generated by plating cells at a density of 1 cell per well in a 96-well plate. HuMECs were exposed to an initial 2 Gy dose of X-irradiation (2.5 Gy/min) followed by an additional dose of either 1 or 2 Gy.

Clonogenic assay
Parental MCF-10A cells and cells from the 80 Gy population were plated at a density of 200 cells per well in a 6-well plate and irradiated (0-15 Gy) 24 h later. Cell colonies were allowed to grow for 7 days before fixation with 3:1 methanol:acetic acid and staining with crystal violet. Colonies were counted by two independent researchers from duplicate wells in three independent experiments.

Genome-wide SNP array analysis
Genomic DNA was extracted with a QIAmp DNA Mini Kit (Qiagen, Limburg, The Netherlands) and analysed by Affymetrix Human SNP6.0 or Cytoscan Array (Affymetrix). Analysis of untreated MCF-10A cells identified acquired trisomy 7, 8, 11, 13 and 19, in addition to the trisomy 20 identified previously in parental MCF-10A cells. 20 There was no evidence of any other acquired copy number alterations in the genome of untreated MCF-10A cells, other than those identified in parental MCF-10A cells.

G-band karyotyping of MCF-10A cells
Metaphase chromosome spreads were prepared by incubating proliferating cells with 100 ng/ml colcemid for 4 h followed by resuspension in 75 mM KCl for 7 min. Cells were fixed by resuspension in 3:1 methanol: acetic acid before karyotyping and FISH analysis. Slidefixed cells were incubated overnight at 60 °C and G-banded by soaking in the trypsin solution (1.9 mg/ml trypsin, 74 mM NaCl, 0.469 mg/ml NaH 2 PO 4 and 0.937 mg/ml Na 2 HPO 4 ) for 10 s and in the staining solution (8 ml Giemsa stain, 0.5 ml Leishman stain and 40ml Gurr buffer (0.469 mg/ml NaH 2 PO 4 and 0.937 mg/ml Na 2 HPO 4 )) for 3 min. Twenty metaphase chromosome spreads were analysed for each population and the karyotypes recorded. centromere 8 (aqua) and IGH (green) copy number status of HuMECs was determined using the Abbott IGH/MYC/CEP8 Tri-colour Dual Fusion Translocation Probe (Abbott Molecular). Slides were heated to 72 °C for 5 min and then incubated for 24 h at 37 °C in a humidified hybridisation chamber (HYBrite; Abbott Molecular). After hybridisation, slides were counterstained with 4′,6-diamidino-2-phenylindole (Vector Laboratories, Peterborough, UK). FISH was scored with an Olympus BX-61 fluorescence microscope (Olympus, Southend-on-Sea, UK) with a ×100 oil objective. Images were analysed using the CytoVision 7.2 SPOT counting system (Leica Microsystems, Gateshead, UK). A minimum of 100 (for MCF-10A) or 70 (for HuMECs) nuclei were scored per test by two independent analysts.

Breast cancer cases
This study was approved by the United Kingdom National Research Ethics Committee (nos 06/Q1108/91 and 07/Q0904/25). Breast cancer tissue was obtained from 18 women who had received radiotherapy to the chest for Hodgkin lymphoma (termed 'radiogenic breast cancer' samples). An age-and tumour-type matched series of breast cancer cases was selected from patients with no history of prior cancer or therapeutic radiation exposure (termed 'sporadic breast cancer' samples). hybridised separately to isolated nuclei because dual hybridisation did not produce strong enough signal for several samples. FISH protocols were the same as described above except that the samples were incubated at 85 °C for 30 min and then hybridised for 48 h at 37 °C. FISH was successful for 20 of 33 (61%) sporadic breast cancer samples and 9 of 18 (50%) radiogenic breast cancer samples and 100 nuclei were scored for each probe by two independent analysts.

Immunohistochemistry
Formalin-fixed, paraffin-embedded breast tissue was dewaxed, rehydrated and antigen retrieval was achieved by incubation in 10    FISH analysis of c-MYC copy number and chromosome 8 copy number in sporadic and radiogenic breast cancers. c-MYC copy number was assessed in tumour cells from radiogenic cancers (n = 9) and from sporadic cancers (n = 20). c-MYC copy number was higher in the radiogenic cancers (Mann-Whitney U-test; P = 0.027) (a). The wider horizontal bars represent the median c-MYC copy number and the narrower horizontal bars represent the 10th and 90th percentiles of the data. The percentage of samples in which at least 10% of the nuclei contained ≥ 3, 4, 5 and 6 copies of c-MYC was compared (b) and was significantly higher in the radiogenic cohort than in the sporadic cohort for ≥ 6 copies of c-MYC (Fisher's exact test; P = 0.022 (*)). The ratio between c-MYC and chromosome 8 centromere copy number was higher in the radiogenic cohort than in the sporadic cohort (Mann-Whitney U-test; P = 0.016) (c). The percentage of samples in each cohort, which had a c-MYC to chromosome 8 centromere ratio ≤ 1.10 (no or little evidence of c-MYC amplification) or >1.10 (evidence of c-MYC amplification) was also compared (d) (Fisher's exact test; P = 0.010).   c-MYC protein expression in radiogenic and sporadic breast cancers. Formalin-fixed, paraffin-embedded tissue from sporadic (n = 33) and radiogenic (n = 18) breast cancers were sectioned and analysed by immunohistochemistry with a specific c-MYC antibody as described in the Materials and methods. The level of c-MYC expression was quantified by derivation of a histoscore. c-MYC expression in the sporadic and radiogenic breast cancers was compared for all cases (a) and was higher in radiogenic cases in which more than 10% of the nuclei had detectable c-MYC expression (Mann-Whitney U-test: P<0.001) (b). The proportion of sporadic and radiogenic breast cancer that had c-MYC expression histoscores of 0-50, 51-100 and >100 were compared (χ 2 : P = 0.018) (c). The number of samples in each group in panel (c) is identified above each bar of the histogram. c-MYC expression is shown in tumours known to have a c-MYC copy number of <3 (n = 22) or ≥ 3 (n = 7) (d).
The wider horizontal bars represent the median c-MYC copy numbers and the narrower horizontal bars represent the 10th and 90th percentiles of the data (a, b and d).